股票 › HALO
哈洛泽生物 HALO
美股市值排名 #1314
$103.63 −$19.33 (-15.72%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $103.75 +0.12%
开盘$117.03
昨收$122.96
当日区间$102.52 – $118.26
成交量6.16M
市值$11.81B
市盈率（TTM）25.9
股息率–
HALO 相关新闻
匹配 Halozyme Therapeutics 或代码 HALO 的头条新闻，按最新排序。
- Analysts' Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)
- H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115
- Form 144 | Halozyme Therapeutics(HALO.US) Director Proposes to Sell 3.64 Million in Common Stocks
- Halozyme Therapeutics(HALO.US) Officer Sells US$6.44 Million in Common Stock
- A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $93 to $115
- Halozyme Therapeutics(HALO.US) Officer Sells US$6.28 Million in Common Stock
- RIMBACO: JOINT ANNOUNCEMENT1. CLOSE OF MANDATORY UNCONDITIONAL CASH OFFER BY CMB INTERNATIONAL CAPITAL LIMITED AND CEB INTERNATIONAL CAPITAL CORPORATION LIMITED FOR AND ON BEHALF OF AUREOLE HALO LIMITED TO ACQUIRE ALL THE ISSUED SHARES OF RIMBACO GROUP GLOBAL LIMIT
- H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95
- Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75
- Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57 正面
- Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93
- J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
- China Resources Land Life (1209.HK): A leading operator of consumer‑focused HALO assets in China.
- TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96
- Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41 负面
暂无评论——快来第一个聊聊 HALO。
登录后参与讨论。